Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced preclinical results that further support varlilumab’s expansion into combination studies with PD-1 inhibitors. The data were presented in a poster session entitled “Synergistic anti-tumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site” at the 2015 American Association for Cancer Research Annual Meeting.
Varlilumab is a fully human immunoglobulin (Ig)G1 agonist antibody that binds to and activates CD27, a critical T-cell co-stimulatory molecule in the immune-activation cascade. Specific and controlled activation of CD27 in the presence of T-cell receptor (TCR) signaling by varlilumab results in enhanced immune responses with a favorable safety profile. Varlilumab is in clinical development for a range of cancers in combination with other therapies that target potentially synergistic points of immune-regulation, including with Opdivo®, BMS’s PD-1 blocking antibody and with MPDL3280A, Roche’s anti-PDL1 investigational cancer immunotherapy.
“These latest studies demonstrate that the combination of varlilumab and anti-PD-L1 induces a potent immune-mediated effect that results in important changes in the tumor microenvironment,” said Tibor Keler, PhD, Co-founder, Executive Vice President and Chief Scientific Officer of Celldex Therapeutics. “Most notably, we observed that the combination strategy improved the ratio of effector T cells to regulatory T cells, which was accompanied by a reduction in the expression of PD-1 on both effector and regulatory T cells. Overall these studies, along with our clinical data where varlilumab has demonstrated anti-tumor activity with minimal toxicity in advanced, refractory disease, provide strong rationale for us to broadly explore varlilumab in combination with a number of complementary investigational and approved oncology drugs, including agents that work through the PD-1 signaling blockade.”
The combination of varlilumab and anti-PD-L1 resulted in a significant improvement in survival over monotherapy in multiple preclinical tumor models, including a CT-26 colon model, an E.G7 thymoma model and a BCL1 disseminated lymphoma model. The properties of the BCL1 lymphoma model allowed for further analysis into the mechanism of synergy between varlilumab and anti-PD-L1. Importantly, mice cured by the combination therapy were shown to have developed protective immunity against the BCL1 tumor, demonstrating that a long lasting and potent memory response was generated during treatment. Additional key observations were made by analyzing the spleens (the primary site of tumor growth) following treatment. The major changes associated with the combination therapy included:
- A greater reduction in tumor cells (as measured by % decrease in CD19+ cells)
- Increased numbers of functional CD4+ and CD8+ T cells (as measured by IFNγ production)
- An increase in the ratio of CD8+ T cells (effector T cells) to regulatory T cells or Tregs
- A notable increase in myeloid cells, particularly neutrophils
These changes at the site of tumor growth, particularly the balance between effector T cells and regulatory T cells, are consistent with an immune-mediated effect resulting in the destruction of tumor cells. The increase in myeloid cells merits further investigation into their role in the combination therapy effect. Other changes including increases in natural killer cells and decreased PD-1 expression on T cells were noted, but these were similar in magnitude to the monotherapy treatments. (Original Source)
Shares of Celldex Therapeutics opened today at $27.03 and are currently trading up at $27.74. CLDX has a 1-year high of $32.82 and a 1-year low of $10.76. The stock’s 50-day moving average is $28.34 and its 200-day moving average is $20.83.
On the ratings front, Celldex has been the subject of a number of recent research reports. In a report issued on April 6, Roth Capital analyst Joseph Pantginis initiated coverage with a Buy rating on CLDX and a price target of $43, which implies an upside of 59.1% from current levels. Separately, on March 11, Cowen’s Boris Peaker reiterated a Buy rating on the stock and has a price target of $33.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joseph Pantginis and Boris Peaker have a total average return of 13.6% and 38.8% respectively. Pantginis has a success rate of 56.4% and is ranked #76 out of 3573 analysts, while Peaker has a success rate of 64.8% and is ranked #23.
In total, 6 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $27.03 which is 30.7% above where the stock opened today.
Celldex Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the development, manufacturing and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.